[go: up one dir, main page]

PE20070175A1 - Derivados de n-[(1,5-difenil-1h-pirazol-3-il)metil]sulfonamida y su preparacion - Google Patents

Derivados de n-[(1,5-difenil-1h-pirazol-3-il)metil]sulfonamida y su preparacion

Info

Publication number
PE20070175A1
PE20070175A1 PE2006000807A PE2006000807A PE20070175A1 PE 20070175 A1 PE20070175 A1 PE 20070175A1 PE 2006000807 A PE2006000807 A PE 2006000807A PE 2006000807 A PE2006000807 A PE 2006000807A PE 20070175 A1 PE20070175 A1 PE 20070175A1
Authority
PE
Peru
Prior art keywords
methyl
pirazol
alkyl
dichlorophenyl
chlorophenyl
Prior art date
Application number
PE2006000807A
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Philippe Pointeau
Murielle Rinaldi-Carmona
Serge Martinez
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20070175A1 publication Critical patent/PE20070175A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS N-[(1,5-DIFENIL-1H-PIRAZOL-3-IL)METIL]SULFONAMIDAS DE FORMULA (I), EN DONDE R1 ES ALQUILO(C1-C12), CARBOCICLO NO AROMATICO(C3-C12), METILO SUSTITUIDO CON CARBOCICLICO NO AROMATICO, FENILO, BENCILO, ENTRE OTROS Y OPCIONALMENTE SUSTITUIDOS; R2 ES H, ALQUILO(C1-C4) O ALQUIL(C1-C4)SULFONILO; R3 ES CIANO, HIDROXILO, ALCOXI(C1-C4), ENTRE OTROS; R4 Y R5 SON INDEPENDIENTEMENTE FENILO OPCIONALMENTE SUSTITUIDOS CON HALOGENO, ALQUILO(C1-C7), ENTRE OTROS. SON PREFERIDOS: N- {[5-(4-CLOROFENIL)-4-CIANO-1-(2,4-DICLOROFENIL)-1H-PIRAZOL-3-IL]METIL}-3-CIANOBENCENOSULFONAMIDA, N- {[5-(4-CLOROFENIL)-4-CIANO-1-(2,4-DICLOROFENIL)-1H-PIRAZOL-3-IL]METIL}-3-TRIFLUOROBENCENOSULFONAMIDA, N- {[5-(4-CLOROFENIL)-4-CIANO-1-(2,4-DICLOROFENIL)-1H-PIRAZOL-3-IL]METIL}-3-TRIFLUOROMETOXIBENCENOSULFONAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON ANTAGONISTAS DE LOS RECEPTORES DE CANABINOIDES CB1 Y SON UTILES PARA EL TRATAMIENTO DE MIGRANA, EPILEPSIA, ALZHEIMER, PARKINSON, TEMBLORES, DISTONIA
PE2006000807A 2005-07-08 2006-07-06 Derivados de n-[(1,5-difenil-1h-pirazol-3-il)metil]sulfonamida y su preparacion PE20070175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507360A FR2888236B1 (fr) 2005-07-08 2005-07-08 Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20070175A1 true PE20070175A1 (es) 2007-02-23

Family

ID=35872804

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000807A PE20070175A1 (es) 2005-07-08 2006-07-06 Derivados de n-[(1,5-difenil-1h-pirazol-3-il)metil]sulfonamida y su preparacion

Country Status (7)

Country Link
AR (1) AR057660A1 (es)
DO (1) DOP2006000163A (es)
FR (1) FR2888236B1 (es)
GT (1) GT200600296A (es)
PE (1) PE20070175A1 (es)
TW (1) TW200800910A (es)
UY (1) UY29657A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297710B1 (en) 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
FR2911136B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
CN113200850A (zh) * 2021-05-08 2021-08-03 渭南师范学院 一种α-酰氧基酮化合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AR057660A1 (es) 2007-12-12
GT200600296A (es) 2007-03-14
FR2888236A1 (fr) 2007-01-12
TW200800910A (en) 2008-01-01
FR2888236B1 (fr) 2007-09-21
UY29657A1 (es) 2007-01-31
DOP2006000163A (es) 2007-02-15

Similar Documents

Publication Publication Date Title
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
NO20074390L (no) Forsterket bimatoprost oye-opplosning
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20050598A1 (es) Compuestos moduladores de cb1
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
PE20081530A1 (es) Nuevos compuestos 617
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
AR064459A1 (es) Derivados de sulfonamida
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
ATE411289T1 (de) Indolalaninderivate als selektive s1p4-agonisten
PE20140968A1 (es) Derivados de benzamida sustituida
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
PE20060610A1 (es) Derivados tetraciclicos como moduladores de los receptores de estrogeno
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1

Legal Events

Date Code Title Description
FC Refusal